CCAT2 and breast carcinoma: For example, Roxana team evaluated the expression of lncRNA CCAT2 by reverse transcription-qPCR and in situ hybridization (ISH) in breast carcinoma tissue and adjacent tissues [10], which indicated that CCAT2 could be act as a novel biomarker to predict the clinical outcome.